IDEXX Laboratories, Inc. $IDXX Stock Position Lifted by William Blair Investment Management LLC

William Blair Investment Management LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 306,107 shares of the company’s stock after buying an additional 7,953 shares during the quarter. William Blair Investment Management LLC owned approximately 0.39% of IDEXX Laboratories worth $159,846,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of IDXX. Bank of New York Mellon Corp acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $628,223,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after acquiring an additional 288,471 shares during the period. International Assets Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 30,484.1% during the third quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock valued at $122,336,000 after acquiring an additional 233,508 shares during the period. Alyeska Investment Group L.P. lifted its stake in shares of IDEXX Laboratories by 97.3% during the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after acquiring an additional 197,808 shares during the period. Finally, American Capital Management Inc. bought a new position in IDEXX Laboratories in the second quarter valued at about $85,341,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. BTIG Research dropped coverage on IDEXX Laboratories in a research report on Friday, October 30th. They issued a “buy” rating for the company. UBS Group upped their target price on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Citigroup raised their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group lowered their price target on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

Read Our Latest Report on IDXX

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $704.23 on Monday. The firm has a fifty day moving average of $562.41 and a two-hundred day moving average of $573.52. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. The stock has a market capitalization of $55.48 billion, a price-to-earnings ratio of 47.49 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the company earned $3.22 EPS. The firm’s revenue was up 9.9% on a year-over-year basis. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Mazelsky sold 25,140 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the transaction, the insider owned 83,803 shares of the company’s stock, valued at $58,929,431.57. The trade was a 23.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 41,428 shares of company stock valued at $28,567,934. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Featured Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.